AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 181 min read$HRMY

Budur Kumar sold $1.7M of HRMY

Budur Kumar (CHIEF MEDICAL OFFICER) sold 38,452 shares of Harmony Biosciences Holdings, Inc. (HRMY) at an average of $43.05 ($43.00–$43.05, $1.66M total) across 3 trades over 2026-09-16 to 2026-09-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Budur Kumar
Published Sep 18, 2026, 8:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 8:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$HRMY
Bearish
medium confidence
Mentioned
$HRMY
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HRMYBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings but is unlikely to move the stock significantly.

02

Market read

Routine insider sale with modest monetary value; limited trading relevance.

03

What to watch

10b5‑1 plan execution may mask timing motives; monitor upcoming clinical data releases.

Relevance 5/10Novelty 4/10Timing: filed Sep 18 2026

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$HRMYBearishMedium confidence
Context

Chief Medical Officer Budur Kumar sold 38,452 shares for $1.66M via a 10b5‑1 plan, reducing his stake to 13,115 shares.

Expected impact

Modest short‑term dip, likely within normal volatility range.

Evidence & confidence

Sale size is modest relative to market cap and follows a pre‑arranged plan, limiting informational weight.

Market effects

Sector

Minimal impact on biotech sector; typical insider sales are common.

Regional

No discernible regional effect.

Global

Limited to investors tracking HRMY.

Counterpoint

What could challenge this read

Sale could be purely liquidity‑driven, not a bearish signal.

Key entities

  • Company
    Harmony Biosciences Holdings, Inc.

    Biotech firm listed on Nasdaq under ticker HRMY.

  • Executive
    Budur Kumar

    Chief Medical Officer of Harmony Biosciences.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

HRMY insider trading history →

Related articles

NOV 4
$HRMYMed

Harmony Biosciences 3Q 2026: Revenue $268.92M, Net income $48.2M, EPS $0.81— 10-Q Summary

Harmony Biosciences reported Q3 2026 revenue of $268.92M, up 12.3% YoY, but net income fell 5.2% to $48.2M and EPS declined 6.9% to $0.81. WAKIX revenue grew 12.3% in the quarter, driven by higher shipments and a price increase. The FDA accepted the Pitolisant GR NDA for review, with a target PDUFA date of April 1, 2027. Phase 3 trials for EPX-100 and Pitolisant HD are ongoing, with results expected in 2027. The company also began a Phase 1b study of BP-205.

tradingview.com1 min
NOV 4
$HRMYMedAI 8/10

Harmony Biosciences Reports Q3 Financial Results

Harmony Biosciences Holdings, Inc. (HRMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. ‌ Exhibit 99.1 Harmony Biosciences Reports Q3 Financial Results On Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile ​ WAKIX ® Net Revenue in Q3 of $2

SEC EDGAR 8-K2 min